| Literature DB >> 33160360 |
Naoki Takasaka1, Yoshitaka Seki2, Ikumi Fujisaki2, Shota Uchiyama2, Sachi Matsubayashi2, Akihito Sato2, Yumie Yamanaka2, Kyuto Odashima2, Taisuke Kazuyori2, Aya Seki2, Hiroshi Takeda2, Takeo Ishikawa2, Kazuyoshi Kuwano3.
Abstract
BACKGROUND: Although cigarette smoking may have a negative impact on the clinical outcome of pulmonary tuberculosis (PTB), few studies have investigated the impact of smoking-associated lung diseases. Emphysema is a major pathological finding of smoking-related lung damage. We aimed to clarify the effect of emphysema on sputum culture conversion rate for Mycobacterium tuberculosis (MTB).Entities:
Keywords: Culture conversion; Emphysema; Tuberculosis
Mesh:
Substances:
Year: 2020 PMID: 33160360 PMCID: PMC7648401 DOI: 10.1186/s12890-020-01325-1
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Flow chart of patient selection. EMB, ethambutol; INH, isoniazid; NTM, nontuberculous mycobacteria; RMP, rifampicin
Characteristics of patients with pulmonary tuberculosis with or without emphysema
| Characteristics | Total | With emphysema ( | Without emphysema | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 69.01 ± 15.92 | 69.18 ± 16.35 | 68.85 ± 15.72 | 0.927 |
| Smoking history | 55 (69.62%) | 38 (100%) | 17 (41.46%) | < 0.0001 |
| Current smoker | 26 (32.91%) | 20 (52.63%) | 6 (14.63%) | < 0.001 |
| Alcohol consumption | 27 (34.18%) | 17 (44.74%) | 10 (24.39%) | 0.057 |
| AST (IU/L) | 29.29 ± 25.14 | 33.13 ± 31.65 | 25.73 ± 16.69 | 0.193 |
| ALT (IU/L) | 21.58 ± 21.32 | 24.03 ± 26.06 | 19.32 ± 15.73 | 0.330 |
| Total bilirubin (mg/dL) | 0.55 ± 0.35 | 0.45 ± 0.20 | 0.64 ± 0.43 | 0.011 |
| Diabetes† | 22 (27.85%) | 13 (34.21%) | 9 (21.95%) | 0.225 |
Haemoglobin A1c (%) (missing value = 1) | 6.42 ± 1.50 | 6.40 ± 1.26 | 6.43 ± 1.71 | 0.930 |
| CKD‡ | 19 (24.05%) | 7 (18.42%) | 12 (29.27%) | 0.260 |
| eGFR (mL/min/1.73 m2) | 77.94 ± 40.36 | 79.37 ± 30.10 | 76.61 ± 48.33 | 0.764 |
| Hypoalbuminemia§ | 50 (63.29%) | 31 (81.58%) | 19 (46.34%) | 0.001 |
| Albumin (g/dL) | 3.14 ± 0.76 | 2.93 ± 0.68 | 3.33 ± 0.80 | 0.020 |
| Autoimmunity | 5 (6.33%) | 1 (2.63%) | 4 (9.76%) | 0.361 |
| Steroid use | 8 (10.13%) | 2 (5.26%) | 6 (14.63%) | 0.266 |
| Malignancy | 9 (11.39%) | 4 (10.53%) | 5 (12.20%) | 1.0 |
| CRP (mg/dL) | 5.08 ± 4.35 | 5.58 ± 3.61 | 4.60 ± 4.95 | 0.320 |
| TTD at baseline (days) | 17.19 ± 7.07 | 17.13 ± 7.75 | 17.24 ± 6.47 | 0.944 |
| TTD within 2 weeks at baseline | 54 (68.35%) | 25 (65.79%) | 29 (70.73%) | 0.637 |
| Treated with HREZ | 54 (68.35%) | 27 (71.05%) | 27 (65.85%) | 0.620 |
| Goddard score | 3.24 ± 4.70 | 6.74 ± 4.73 | 0 | < 0.0001 |
Data are means ± SD, n (%)
*We used Fisher’s exact test or Student’s t-test to calculate p- values
†Diabetes: prescription of oral hypoglycaemic agents and/or insulin; fasting blood glucose ≥126 mg/dL or haemoglobin A1c ≥6.5%. ‡ CKD: glomerular filtration rate < 60 mL/min/1.73 m2 for > 3 months. § Hypoalbuminemia: serum albumin ≤3.5 g/dL
SD standard deviation, CKD chronic kidney disease, TTD time to tuberculosis detection, HREZ isoniazid, rifampicin, ethambutol and pyrazinamide
Fig. 2The distribution of Goddard score in the pulmonary tuberculosis patients with emphysema (n = 38)
CT findings in patients with pulmonary tuberculosis with or without emphysema
| CT findings | Total | With emphysema | Without emphysema | |
|---|---|---|---|---|
| Cavities | 45 (56.96%) | 27 (71.05%) | 18 (43.90%) | 0.015 |
| Consolidation | 57 (72.15%) | 32 (84.21%) | 25 (60.98%) | 0.021 |
| Bronchiolitis | 62 (78.48%) | 28 (73.68%) | 34 (82.93%) | 0.318 |
| Nodule/mass | 29 (36.71%) | 16 (42.11%) | 13 (31.71%) | 0.338 |
Data are n (%)
*We used Fisher’s exact test
Fig. 3Proportion of pulmonary tuberculosis (PTB) patients with sputum culture conversion after treatment initiation (with vs without emphysema). Kaplan–Meier curves revealed significantly longer sputum time to culture conversion (TTC) in 38 PTB patients with emphysema (median TCC 52.0 days) than in 41 patients without emphysema (28.0 days) (p < 0.001, log-rank test)
Cox proportional hazard regression unadjusted and adjusted analysis of time to sputum culture conversion*
| Characteristics | Univariate HR (95% CI) | Multivariate HR (95% CI) | |||
|---|---|---|---|---|---|
| Age | 1.01 (0.99–1.02) | 0.483 | 0.994 (0.98–1.01) | 0.593 | |
| Emphysema | 2.21 (1.36–3.60) | 0.001 | 2.43 (1.18–4.97) | 0.015 | |
| Smoking history | 1.81 (1.09–2.99) | 0.021 | 0.87 (0.44–1.72) | 0.692 | |
| Current smoker | 1.26 (0.77–2.04) | 0.361 | |||
| Consolidation | 1.77 (1.06–2.96) | 0.031 | 1.07 (0.61–1.87) | 0.818 | |
| Cavities | 2.72 (1.65–4.49) | < 0.0001 | 2.15 (1.18–3.89) | 0.012 | |
| Alcohol consumption | 1.19 (0.73–1.94) | 0.478 | |||
| Diabetes† | 1.67 (0.99–2.82) | 0.055 | |||
| CKD‡ | 0.83 (0.48–1.41) | 0.482 | |||
| Hypoalbuminemia§ | 1.74 (1.08–2.80) | 0.024 | 0.99 (0.53–1.86) | 0.979 | |
| Autoimmunity | 0.44 (0.18–1.11) | 0.081 | |||
| Steroid use | 0.83 (0.38–1.82) | 0.641 | |||
| Malignancy | 1.02 (0.51–2.06) | 0.956 | |||
| TTD within 2 weeks at baseline | 2.56 (1.52–4.31) | < 0.0001 | 2.95 (1.64–5.31) | < 0.0001 | |
| Treated with HREZ | 1.40 (0.85–2.31) | 0.181 | |||
*HR calculated with each per unit increase. Each variable measured at the time of diagnosis. Adjusted by previously described clinically important variables and candidate variables (age, emphysema, smoking history, consolidation, cavities, hypoalbuminemia and TTD within 2 weeks) for which the p- value was < 0.05 on univariate analysis
†Diabetes: prescription of oral hypoglycaemic agents and/or insulin; fasting blood glucose ≥126 mg/dL or haemoglobin A1c ≥6.5%. ‡ CKD: glomerular filtration rate < 60 mL/min/1.73 m2 for > 3 months. § Hypoalbuminemia: serum albumin ≤3.5 g/dL